| 1.46 -0.07 (-4.58%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.8 |
1-year : | 2.11 |
| Resists | First : | 1.54 |
Second : | 1.81 |
| Pivot price | 1.37  |
|||
| Supports | First : | 1.11 |
Second : | 0.92 |
| MAs | MA(5) : | 1.58 |
MA(20) : | 1.35 |
| MA(100) : | 1.92 |
MA(250) : | 3.23 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 57.2 |
D(3) : | 67.9 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 7.92 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRME ] has closed below upper band by 36.5%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.57 |
| Low: | 1.42 - 1.44 | 1.44 - 1.45 |
| Close: | 1.44 - 1.46 | 1.46 - 1.47 |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Fri, 06 Jun 2025
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Thu, 29 May 2025
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Tue, 27 May 2025
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Thu, 22 May 2025
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Mon, 19 May 2025
Prime Medicine Prioritizes Pipeline, Cuts Workforce By 25% - Stock Plunges - Nasdaq
Mon, 19 May 2025
Prime Medicine Appoints New CEO Amid Restructuring - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 131 (M) |
| Held by Insiders | 6.055e+007 (%) |
| Held by Institutions | 24.1 (%) |
| Shares Short | 16,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 603.2 % |
| Return on Equity (ttm) | -40.4 % |
| Qtrly Rev. Growth | 3.85e+006 % |
| Gross Profit (p.s.) | 94.19 |
| Sales Per Share | -74.33 |
| EBITDA (p.s.) | -9.77871e+007 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -104 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 2.69 |
| Dividend | 0 |
| Forward Dividend | 1.77e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|